C4 Therapeutics shares fall 1.75% in premarket after BioPharma reports clinical progress in targeted protein degradation.

C4 Therapeutics, Inc. fell 1.75% in premarket trading, following reports of clinical advancements in the targeted protein degradation field, including successful Phase III trials by Arvinas and new data from Kymera Therapeutics, highlighting the potential of the technology platform. The company is a clinical-stage biopharmaceutical company focused on targeted protein degradation science, using its TORPEDO platform to develop small molecule drugs that degrade disease proteins to advance oncology projects.